Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00128921
Recruitment Status : Terminated (study terminated due to low accrual)
First Posted : August 10, 2005
Results First Posted : April 26, 2012
Last Update Posted : April 26, 2012
Sponsor:
Information provided by (Responsible Party):
University of Arkansas

Tracking Information
First Submitted Date  ICMJE August 8, 2005
First Posted Date  ICMJE August 10, 2005
Results First Submitted Date  ICMJE April 15, 2011
Results First Posted Date  ICMJE April 26, 2012
Last Update Posted Date April 26, 2012
Study Start Date  ICMJE April 2006
Actual Primary Completion Date February 2008   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 25, 2012)
  • Number of Participants With a Positive Response to Bortezomib Measured by the Bone Marker Parathyroid Hormone [ Time Frame: 6 months ]
    Parathyroid hormone: Any increase in PTH was considered response
  • Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Calcium [ Time Frame: 6 months ]
    Calcium: any Calcium increase would refer to a positive response.
  • Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Alkaline Phosphatase [ Time Frame: 6 months ]
    Alkaline phosphatase: If the Alkaline phosphatase increases it's considered positive response
  • Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Magnesium [ Time Frame: 6 months ]
    Magnesium: Any Magnesium increase would refer to a positive response.
  • Number of Participants With a Positive Response to Bortezomib Measured by Bone Markers Like Phosphate. [ Time Frame: 6 months ]
    Phosphate: any Phosphate increase would refer to a positive response.
Original Primary Outcome Measures  ICMJE
 (submitted: August 9, 2005)
To evaluate the effect of three different doses of VELCADE™ on inducing osteoblast activation as measured by ALP and other bone markers in patients with relapsed/refractory myeloma.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 25, 2012)
Number of Participants With a Positive Response to Bortezomib Measured by Bone Marker Osteocalcin [ Time Frame: 6 months ]
Osteocalcin: Any Osteocalcin increase means positive response.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 9, 2005)
  • To evaluate the association between osteoblastic activation and myeloma response to VELCADE™.
  • To identify predictive factors for Velcade™-associated osteoblastic activation
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
Official Title  ICMJE A Phase II Dose-Response Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
Brief Summary Velcade (bortezomib, PS-341) has recently been approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma for patients who have received at least one prior therapy. Velcade is a unique compound developed by scientists at Millennium Pharmaceuticals, Inc. Velcade enters cells and affects the way they divide. Cancer cells are particularly sensitive. Velcade interferes with the enzyme "proteasome" which is responsible for allowing cells to divide. When cancer cells cannot divide, they die. Velcade falls into the class of drugs known as "proteasome inhibitors."
Detailed Description

Studies at the Myeloma Institute for Research & Therapy have shown that Velcade is very effective in treating patients who are relapsing after having been treated with at least two lines of prior therapy.

One key factor in multiple myeloma is bone destruction caused by the myeloma cells. Most patients with multiple myeloma (80%) will develop skeletal lesions, despite treatment. These lesions are rarely repaired, even when the myeloma is in remission.

Experience at MIRT has suggested that Velcade may increase osteoblast (bone cells that cause bone growth) activity. One goal of this study is to identify if Velcade's effect on myeloma is due to its ability to increase osteoblasts.

This study also has the following goals:

  • To find out the lowest dose of Velcade that has an effect on myeloma and also increases bone activation;
  • To identify ways to predict if Velcade will increase bone activation.

Time periods are:

According to cohort assignment, you will receive three cycles of Velcade®™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21-day cycle.

During the first two cycles of Velcade®™, bone markers (tests on your bones) will be measured Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2 to 4 hours for 8 hours.

Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours)

During the third cycle of Velcade®™, bone markers will be measured Days 1 and 11: Pre-dose and post-dose, and then again on Day 21.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Multiple Myeloma
Intervention  ICMJE Drug: VELCADE™

Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:

Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.

Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated.

Other Name: Bortezomib
Study Arms  ICMJE
  • Experimental: Velcade, Cohort A
    Treatment: 1.3 mg/m^2
    Intervention: Drug: VELCADE™
  • Experimental: Velcade, Cohort B
    Treatment: 1.0 mg/m^2
    Intervention: Drug: VELCADE™
  • Experimental: Velcade, Cohort C
    Treatment: 0.7 mg/m^2
    Intervention: Drug: VELCADE™
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: April 25, 2012)
18
Original Enrollment  ICMJE
 (submitted: August 9, 2005)
30
Actual Study Completion Date  ICMJE February 2008
Actual Primary Completion Date February 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • History of histologically documented MM with relapsed or progressive disease after at least one line of prior therapy.
  • Patient has measurable disease in which to capture response, defined as one or more of the following:

    • Serum M-protein level > 1.0 gm/dl (10.0 g/L) measured by serum protein electrophoresis or immunoglobulin electrophoresis; or
    • Urinary M-protein excretion > 1000 mg/24 hours; or
    • Bone marrow plasmacytosis of > 30% by bone marrow aspirate and/or biopsy; or
    • Serum free light chains (by the Freelite test) > 2 X the upper limit of normal, in the absence of renal failure.
    • Evidence of active disease by radiographic techniques
  • Performance status (PS) of <= 2 as per Southwest Oncology Group scale, unless PS of 3-4 based solely on bone pain.
  • Patients must have a platelet count >= 50,000/mm3, and an absolute neutrophil count of at least 1,000/μl.
  • Patients must have adequate renal function defined as creatinine clearance > 30ml/min.
  • Patients must have adequate hepatic function defined as serum transaminases and direct bilirubin < 2 X the upper limit of normal.
  • Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy test documented within one week of registration. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
  • Male or female adults of at least 18 years of age.
  • Patients must have signed and Institutional Review Board approved written informed consent form and demonstrate willingness to meet follow-up schedule and study procedure obligations

Exclusion Criteria:

  • Chemotherapy or radiotherapy received within the previous 4 weeks.
  • Has received previous bortezomib therapy
  • Significant neurotoxicity, defined as grade > 2 neurotoxicity per National Cancer Institute Common Toxicity Criteria.
  • Platelet count < 50,000/mm3, or ANC < 1,000/μl
  • Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome.
  • Patient has hypersensitivity to bortezomib, boron, or mannitol
  • Clinically significant hepatic dysfunction as noted by bilirubin or AST >3 times the upper normal limit or clinically significant concurrent hepatitis.
  • New York Hospital Association Class III or Class IV heart failure.
  • Myocardial infarction within the last 6 months.
  • Non-secretory multiple myeloma, unless the patient has measurable lesions on computed tomography, magnetic resonance imaging and/or positron emission tomography.
  • Uncontrolled, active infection.
  • Patients with a history of treatment for clinically significant ventricular cardiac arrhythmias.
  • Poorly controlled hypertension, diabetes mellitus, or other serious or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol.
  • Pregnant or potential for pregnancy. Women of childbearing potential will have a pregnancy [beta-HCG] test at screening, and will be required to use a medically approved contraceptive method. Pregnancy testing will be performed prior to administration of each cycle of study drug.
  • Breast-feeding women may not participate.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00128921
Other Study ID Numbers  ICMJE UARK 2004-22
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of Arkansas
Study Sponsor  ICMJE University of Arkansas
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Maurizio Zangari, MD University of Arkansas
PRS Account University of Arkansas
Verification Date April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP